Medicare just became the nation’s first large-scale, reliable buyer of hemp — provided you are old enough, sick enough, and compliant enough to qualify. Everyone else — the twenty-something vaping a delta-8 cart in Austin, the Hill Country soccer mom with a bag of sleep gummies — is staring down a federal crackdown capable of erasing most of the existing retail market within a year. That split screen is the essential fact of American drug policy in 2026: Grandma’s CBD has received its federal blessing, while corner-store delta-8 is being fitted for the gallows.
The $500 Olive Branch, and What It Actually Means
On April 1, the Centers for Medicare & Medicaid Services quietly activated a pilot program allowing certain seniors to receive up to $500 annually in hemp-derived products through participating provider groups. Don’t mistake this for a subsidy program or a reward card you swipe at the Buc-ee’s hemp counter. Beneficiaries cannot walk into their local shop, save the receipt, and bill Washington. Instead, CMS will reimburse organizations operating inside select Innovation Center models — ACO REACH, Enhancing Oncology, and LEAD — up to $500 per eligible patient, with those organizations controlling which products are furnished as part of clinician-guided care plans. The federal government is not subsidizing brands. It is commissioning a tightly controlled cannabinoid experiment on its own terms.
The strings attached are considerable. Products must be hemp-derived and remain within the 0.3 percent delta-9 THC limit established by the 2018 Farm Bill, along with a hard cap of only a few milligrams of total THC per serving. Inhalables, synthetics, and anything with obvious intoxicating potential are excluded. Certain patients — those with disqualifying conditions including some substance use disorders and serious pulmonary disease — are carved out entirely. Dollars flow to accountable care organizations and similar entities, not to beneficiaries directly, which means clinicians and administrators control the tap. For Texas seniors, particularly in rural communities, “legal hemp” is about to acquire a respectable institutional twin: doctor-approved, chart-notated, dispensed through credentialed intermediaries rather than the shop on the frontage road.
FDA’s Wink and Nod — and Who It Leaves Out
To prevent the pilot from colliding with existing law on its first day, the Food and Drug Administration issued a new enforcement memorandum focused on Medicare-linked hemp products. The agency has spent years insisting that CBD in food and supplements occupies an unresolved regulatory gray zone. Now it is signaling a narrow pocket of “enforcement discretion” — an official look-the-other-way — when CBD is dispensed under clinician guidance inside CMS models and meets strict safety, labeling, and potency standards.
That carve-out does not extend to the broader Texas hemp marketplace. Retail tinctures, gummies, beverages, and vapes sold directly to consumers remain burdened by the same unresolved FDA questions, patchwork state rules, and ever-present risk that a compliance misstep converts inventory into contraband. Even brands that have invested seriously in rigorous testing, GMP-style production, and responsible labeling gain no special status from the fact that CMS is quietly paying for distant cousins of their products. Washington has blessed cannabinoid use in a narrow, medicalized lane — and left the general market precisely where it was, except for one item buried in a shutdown bill that threatens to blow everything else up.
The 0.4mg Time Bomb
While the Medicare pilot is launching, a separate piece of federal policy is counting down. Buried in last year’s government funding package to end a shutdown, Congress rewrote the federal definition of “hemp” to impose a hard ceiling of 0.4 milligrams of total THC per finished container — in addition to the already-familiar 0.3 percent delta-9 THC by dry weight. Any hemp-derived cannabinoid product exceeding that threshold will, once the law takes full effect, no longer qualify as hemp at all.
The numbers involved are not abstractions. Lawyers and analysts tracking the change warn that the cap would disqualify virtually all existing full-spectrum and intoxicating hemp products, along with a meaningful share of mainstream CBD items that contain trace THC exceeding the 0.4mg floor across a full bottle. Trade groups and beverage-law specialists estimate that 95 percent or more of current ingestible hemp products are over the line. In Texas alone, estimates peg the hemp market at roughly $8 billion, supported by thousands of jobs in farming, processing, distribution, and retail — an industry that would be, in the words circulating through trade commentary, “effectively shut down” if the cap is enforced as written. What was packaged inside the Beltway as a fix to the “intoxicating hemp loophole” looks, from the I-35 corridor, like a controlled demolition of an industry Washington once invited people to build.
Texas: Fresh Off a Victory, Walking Into an Ambush
No state illustrates the whiplash more vividly than Texas. Earlier this year, a hard push to ban hemp-derived THC products — spearheaded by Lt. Gov. Dan Patrick, backed by substantial Republican leadership — ran headlong into a mobilized hemp industry and a governor who ultimately vetoed the ban. The fight was real: hearing rooms filled, phone lines lit up, and small business owners made the case that prohibition would gut a multi-billion-dollar market. When the veto ink dried, many Texas operators concluded they had bought themselves at least a few years of breathing room.
Then came the federal shutdown deal. Buried in that compromise is the 0.4mg cap that accomplishes, at the national level, almost exactly what the failed Texas ban would have accomplished within one state. Nearly all consumable hemp products with any meaningful THC content become unlawful — not just in Houston and Lubbock but in Boise and Buffalo. The same operators who spent months fighting Austin now find themselves on the receiving end of a Washington decision they had virtually no hand in shaping. The sense of ambush is not rhetorical. It is palpable in every industry conversation and in local coverage from San Antonio to Dallas.
A Split Screen Made for Political Conflict
The juxtaposition is difficult to ignore. On one side of the screen, Medicare dips a cautious institutional toe into hemp, allowing clinicians in select models to furnish carefully constrained CBD and low-THC products as part of structured care plans. On the other, Congress and federal agencies have redefined hemp in a way that treats nearly anything beyond a trace as beyond the pale. One program recognizes cannabinoids as legitimate tools for managing pain, sleep, and chronic conditions — provided they arrive small, boring, and physician-mediated. The other treats any cannabinoid product that people actually choose to buy as a loophole to be sealed.
For Texas officeholders, this creates a set of choices that will not stay quiet. Supporting the federal 0.4mg cap means endorsing a Washington compromise that threatens to dismantle an $8 billion in-state industry that their own voters just finished defending against a home-grown ban. Backing the Medicare pilot, on the other hand, means conceding that cannabinoids are legitimate medicine for the very population most likely to appear in Republican primary elections — which undercuts a good deal of the rhetoric used to justify state-level crackdowns. Trying to ignore the contradiction does not make it disappear. Washington is now setting the terms for a sector that Texas policymakers thought they had partially tamed on their own.
Two Experiments, One State on the Line
From a policy standpoint, the United States is running two concurrent experiments. In the Medicare pilot, CMS and its partners will gather data on whether clinician-guided hemp products reduce pain, improve sleep, or lower downstream costs in selected patient populations, using the $500 annual ceiling as both incentive and constraint. In the broader economy, the new hemp definition and 0.4mg cap will test how resilient an industry can be when its core products are redefined into illegality by a few lines in a funding bill nobody was watching closely enough.
For Texas, which embraced hemp as a politically viable middle ground when broader cannabis reform remained a bridge too far, the stakes of both experiments are anything but theoretical. Producers, processors, and retailers were told the rules: test your products, get licensed, pay your taxes, and you can build a durable business under state and federal law. Now they are learning that the most important rule was always subject to renegotiation in a distant capital, with local investment and livelihoods treated as acceptable collateral. Whether Texas responds to that reality with the same ferocity it brought to Austin, or accepts it as the price of playing in a federally defined market, will say a great deal about whose experiment this actually is — and who gets to survive it.
Rapper turns police raid into music… and wins on free speech Afroman just proved something loud and clear:
You can turn a police raid into a hit song — and win in court.
The rapper, best known for “Because I Got High,” came out victorious in a defamation lawsuit filed by seven Ohio sheriff’s deputies after he used footage of a 2022 raid on his home in a series of music videos.
FROM RAID TO RECORD
The whole situation started when law enforcement raided Afroman’s house on suspicions of drug activity and kidnapping.
They came in heavy…
Guns drawn
House searched
Property damaged
And found nothing.
No charges. No arrests. No case.
THEN HE DID WHAT ARTISTS DO
Instead of staying quiet, Afroman flipped the script.
He took home security footage of the raid and turned it into content — dropping viral music videos, including tracks off his “Lemon Pound Cake” project.
One clip even shows an officer distracted by a cake sitting on the counter — a moment that became internet gold.
THE LAWSUIT
The deputies didn’t find it funny.
They sued Afroman for defamation, claiming:
He damaged their reputations
They faced harassment after the videos dropped.
They deserved millions in damages
(Reportedly close to $4 million.)
THE VERDICT
The court didn’t buy it.
A jury sided with Afroman, ruling that his videos and music were protected under free speech, not defamation.
After the win, Afroman summed it up in true fashion:
“We did it… Freedom of speech.”
WHY THIS MATTERS
This case hits bigger than one rapper.
It’s about:
Free speech vs. law enforcement power
Art as protest
Who controls the narrative after a raid goes wrong.
Afroman didn’t just defend himself — he turned the system into content… and beat it at its own game.
Our BLAZED TAKE
Let’s be real…
They kicked in his door, found nothing, and then got mad when he made a song about it.
That’s not defamation —
that’s storytelling.
And now there’s a legal precedent backing it up. It was absolutely hilarious watching him on the stand last week absorbing everything the DA threw at Afroman, as he stood there in his USA flag suit and sun glasses, and he leaned right back into the prossicuter, throwing body shots, 1st Ammendment, then 4th Ammendment.
As a monthly practitioner of the 1st amendment we are most proud of you Afroman and would love to get you on the podcast.
As lawmakers move closer to cracking down on hemp-derived THC products, the alcohol industry is stepping into the fight—and surprisingly, they’re not calling for prohibition.
Instead, a major alcohol trade group is urging Congress to regulate hemp THC beverages rather than ban them outright, arguing that a structured framework would protect consumers while preserving a fast-growing market.
The push comes as federal lawmakers consider policies that could effectively wipe out the booming hemp beverage sector, which has exploded in popularity as an alternative to alcohol.
Regulation Over Prohibition
The alcohol industry’s position is simple:
Set clear rules
Enforce age restrictions
Require testing and labeling
Treat THC drinks more like alcohol than contraband
Their argument? A ban won’t eliminate demand—it will just drive the market underground.
A Billion-Dollar Battle
Hemp-derived THC drinks have quickly become one of the hottest segments in cannabis, appealing to consumers looking for a legal buzz without alcohol. But that growth has also put a target on the industry’s back.
With federal changes looming—including tighter definitions of THC that could outlaw many current products—the stakes are massive.
The Bigger Picture
This isn’t just about drinks—it’s about the future of hemp itself.
Regulators want control
Lawmakers are split between bans and oversight Industries—from cannabis to alcohol—are jockeying for position
And now, even Big Alcohol is signaling something the hemp industry has been saying all along:
Regulation works. Prohibition doesn’t.
Bottom Line
As the fight over hemp intensifies, one thing is clear—this isn’t a fringe issue anymore.
When the alcohol industry starts lobbying to protect THC products, you know the game has changed.
While out-of-state vendors are not directly bound by the Texas Department of State Health Services (DSHS) retail ban, ordering THCA flower into Texas after
March 31, 2026, carries significant legal and practical risks.
Retail Ban Scope: The new DSHS rules specifically prohibit the manufacture, distribution, and retail sale of smokable hemp products (like THCA flower) within the state of Texas.
Out-of-State Loophole: Because DSHS regulations primarily govern Texas-licensed businesses, some out-of-state operators may continue to ship to Texas. However, Texas law requires any business selling consumable hemp products to Texas residents to register with the state, which may lead many reputable vendors to stop shipping to avoid legal conflict.
Confiscation Risk: Law enforcement can seize packages they suspect contain illegal substances. Under the new “total THC” calculation effective March 31, most THCA flower will test above the 0.3% limit, allowing the state to classify it as illegal marijuana.
State vs. Federal Conflict: While THCA flower may be federally compliant under the 2018 Farm Bill (based on Delta-9 levels), Texas’s stricter “total THC” standard means these products can be treated as controlled substances once they enter the state.
Possession Status: Current DSHS rules target the sale and distribution, not the possession by individuals. However, since THCA flower is physically indistinguishable from illegal marijuana without lab testing, possession still carries a high risk of “legal scrutiny” or arrest.
The direct answer is a qualified yes, but with significant risks and requirements. The new DSHS rules primarily govern the manufacture, distribution, and retail sale of hemp products within the state of Texas.
Here is how out-of-state vendors are impacted:
DSHS Registration Requirement: Any online retailer based outside of Texas that sells consumable hemp products to Texas residents is still required to register with the DSHS.
Retail Sale Loophole: The Texas Supreme Court has previously upheld that while Texas can ban the manufacturing of smokable hemp in-state, it cannot necessarily ban the retail sale of smokable products manufactured elsewhere, provided they meet state testing and labeling standards.
The “Total THC” Conflict: The new rule changes the state’s calculation to Total THC (THCA + Delta-9). While an out-of-state vendor might be legal in their home state, once the product enters Texas, it may be classified as illegal marijuana if it exceeds the 0.3% Total THC limit.
Vendor Risks and Compliance Out-of-state vendors will likely fall into two categories:
Risk-Averse Vendors: Many major out-of-state brands are already announcing they will stop shipping THCA flower to Texas to avoid potential legal conflict with state authorities or to prevent their products from being seized by law enforcement.
Gray Market Vendors: Some smaller or less cautious vendors may continue shipping, relying on the fact that DSHS rules target businesses rather than consumer possession.
Summary of What Remains “Safe” for Vendors
Many featured vendors, may offer the most “legally secure” products to sell to Texans from out-of-state after March 31 include:
Hemp-derived Delta-9 Edibles: These are fully compliant because they are formulated based on dry weight and do not rely on the THCA-to-THC conversion math.
Tinctures and Topicals: These products are generally unaffected by the smokable ban.
CBD Products: Standard CBD oils and isolates remain legal under both state and federal frameworks.
As geopolitical tensions escalate around the world, a growing number of analysts and independent media commentators are warning about the potential for a “false flag” event — an attack carried out in a way that falsely blames another party (in this case, Iran); in order to justify war or political action.
The conversation has resurfaced following renewed military tensions involving Iran and the United States in early 2026. Some commentators believe that if the conflict expands, a dramatic incident blamed on a foreign adversary could be used to rally domestic support for deeper military involvement.
A Pattern of Suspicion in Modern Warfare
The concept of false-flag operations isn’t new. Throughout history, critics of governments and intelligence agencies have pointed to controversial events and covert operations as examples of how governments sometimes manipulate public perception during wartime. Independent commentators argue that when officials begin warning about potential terror attacks or external threats, those narratives can sometimes function as political messaging designed to prepare the public for major policy decisions.
While these claims remain highly debated and often controversial, they reflect a growing distrust among segments of the public toward government institutions, intelligence agencies, and mainstream media coverage of international conflicts. War Messaging and Public Opinion One concern raised by critics is that emotionally powerful events — especially attacks on civilians — can dramatically shift public opinion. Historically, major incidents have sometimes triggered rapid political unity behind military action.
According to critics of modern war policy, a shocking domestic attack blamed on a foreign power could instantly generate public support for expanded conflict or new emergency powers.
Whether those fears are realistic or speculative, the discussion highlights a broader issue: how modern governments communicate threats and how quickly public sentiment can change during moments of crisis.
A New Media Landscape
Unlike previous decades, today’s information ecosystem is far more decentralized. Independent media platforms, podcasts, and social media networks now challenge official narratives in real time.
This means that any major geopolitical event is likely to be scrutinized instantly by analysts, journalists, and citizen investigators around the world.
Supporters of this decentralized media environment say it increases transparency and accountability.
Critics argue it also makes it easier for misinformation and speculation to spread rapidly.
Staying Informed Without Fear
Experts generally advise the public to approach dramatic geopolitical claims carefully, especially during periods of rising international tension.
The best defense against manipulation — whether from governments, foreign actors, or viral misinformation — is critical thinking, reliable sourcing, and patience before drawing conclusions.
As global conflicts evolve, one thing remains certain: information warfare is now as powerful as traditional weapons, and understanding how narratives are shaped may be just as important as understanding the battlefield itself.
In case you missed it, a new op-ed in the Washington Examiner highlights a critical public-policy issue: the federal prohibition on intoxicating hemp products that Congress passed into law with bipartisan support last November must be fully implemented this year, without delay.
With the U.S. House Committee on Agriculture set to begin markup of the Farm, Food, and National Security Act of 2026 – also known as the Farm Bill – on March 3rd, the intoxicating hemp industry is pushing hard to keep these products on the market.
But as Diane Carlson writes, “the measure passed with a rare bipartisan supermajority of 76 senators. It reflected what harmed families, emergency physicians, leading public health and youth-serving organizations, law enforcement, regulators, and 39 state attorneys general, both Democrat and Republican, had already concluded: this loophole had become a national public-health crisis. It was causing unacceptable harm to children, families, and communities nationwide.”
Carlson, who is the co-founder and national policy director of One Chance to Grow Up, a nonpartisan, nonprofit organization that educates and advocates children’s interests in marijuana policy, goes on to note that “in the “Wild West” of the intoxicating hemp market, there are no age gates, no testing standards, no ingredient disclosures, no warnings. The only assured variable is predictable harm from those building businesses off targeting children and deceiving the public through “dupe” products and false claims.”
Background: A provision signed into law last November will end the nationwide unregulated sale of psychoactive Tetrahydrocannabinol (THC) products disguised as “hemp” or cannabidiol (CBD). These items have flooded gas stations, convenience stores and online marketplaces with gummies, vapes and drinks that can rival marijuana in potency and typically appeal to children. The prohibition is set to take effect this November, but the intoxicating hemp industry is seeking to delay implementation of the law.
The Problem: Since 2018, bad actors exploited hemp regulations to create unregulated, lab-produced intoxicants (gummies, vapes, drinks) with THC levels matching regulated marijuana markets but are sold without age gates, testing standards or ingredient disclosures.
The Harm: The consequences are real. The loophole has contributed to accidental child poisonings, emergency room visits, impaired driving incidents and serious mental health concerns.
Carlson writes “the intoxicating hemp free-for-all led to the rise of accidental child poisonings and injuries, ER visits and hospitalizations, impaired driving, and other serious physical and mental health effects, including acute psychosis that, for some, led to suicide.”
The Solution: The closure doesn’t ban hemp or eliminate CBD – it simply ensures intoxicating products can’t be marketed as “hemp” and sold in easily accessible stores and locations. Implementation cannot be delayed if we’re serious about protecting children and families.
“If a product can intoxicate, it should not be marketed as wellness ‘hemp’ and sold next to everyday candies, snacks, and drinks outside of a voter-approved marijuana dispensary.”
Congress acted. Now the law must take effect on schedule. Protecting kids from unregulated intoxicating products should not be controversial, it should be common sense.
The Texas hemp industry does not have a marketing problem. It has a credibility problem.
That distinction matters.
When legislators talk about “unregulated intoxicants,” when law enforcement conducts raids with television cameras in tow, when opponents describe the market as a public health emergency, they are not arguing about cannabinoids. They are arguing about discipline. They are arguing about whether this industry behaves like an adult.
Good Manufacturing Practice—GMP—is the answer to that argument.
GMP is not a logo. It is not a slogan. It is not a sticker on a window. It is a system. At its core, GMP means this: products are manufactured in a controlled, documented, repeatable way that ensures consistency, safety, and traceability. It requires written procedures. It requires training. It requires recordkeeping. It requires the ability to answer a simple question without hesitation: “How do you know this batch is what you say it is?”
If you cannot answer that question with documentation, you are not in a regulated market. You are in a hobby.
The federal framework for GMP in the United States exists already. The Food and Drug Administration enforces current Good Manufacturing Practice, or cGMP, standards for foods, dietary supplements, cosmetics, and pharmaceuticals. Dietary supplements, for example, are governed by 21 C.F.R. Part 111. Food facilities operate under 21 C.F.R. Part 117. These are not abstract rules. They cover sanitation controls, supplier verification, batch production records, equipment maintenance, complaint handling, and recall procedures.
Hemp-derived products sit in a complicated regulatory posture, but that does not mean they sit in a vacuum. The scientific principles of GMP apply whether a product contains vitamin C or a cannabinoid.
The core concept is control. Control of raw materials. Control of processes. Control of environments. Control of records.
Consider what that looks like in practice. A manufacturer sources distillate. Under a GMP system, that supplier is qualified. Certificates of analysis are verified and tied to lot numbers. Incoming material is logged. Storage conditions are documented. Production steps are written in standard operating procedures. Employees are trained and their training is recorded. Each batch is assigned a number. Finished goods are tested. Distribution records show where each lot was shipped. If a defect is discovered, there is a documented recall plan.
That is not bureaucracy. That is civilization.
Hemp is a plant. Plants bioaccumulate heavy metals from soil. They host microbes if improperly dried. They degrade if stored in humid environments. Cannabinoids oxidize. Residual solvents can remain if extraction is sloppy. None of this is scandalous. It is chemistry. GMP exists to manage these variables, not to eliminate business.
The uncomfortable truth is that parts of the hemp market grew faster than their infrastructure. Entrepreneurs moved at startup speed. Regulation moved at legislative speed. Public perception moved at cable news speed. Those timelines collided.
When opponents point to mislabeled potency, contaminated products, or products marketed without guardrails, they are not inventing physics. They are pointing to variance. Variance is what GMP is designed to reduce.
Here is the forward-looking reality: industries that survive scrutiny are industries that document themselves into legitimacy. The food industry did not always have Hazard Analysis and Critical Control Points. The pharmaceutical industry did not always have batch validation. They built those systems because crises forced maturity.
Hemp can build them proactively.
This is not about surrendering to overregulation. It is about seizing narrative control. An industry that can show documented SOPs, training logs, supplier verification, sanitation schedules, and traceable batch records is not “the Wild West.” It is a regulated commercial ecosystem waiting for consistent oversight.
Legislators respond to evidence. Regulators respond to structure. Courts respond to documentation.
GMP transforms debate. Instead of arguing in the abstract about “dangerous products,” the conversation becomes concrete: show the batch record, show the COA, show the sanitation log, show the training file.
When you can produce those documents without panic, rhetoric loses oxygen.
There is a deeper point here. Credibility is cumulative. It is built through systems, not speeches. If the hemp industry wants durable access to markets, capital, insurance, and mainstream retail partnerships, it must look and operate like an industry that expects to be around in ten years.
GMP is not glamorous. It is binders and databases. It is checklists and calibration logs. It is the quiet confidence of being able to say, under oath if necessary, “Here is exactly how we made this product.”
In a climate where fear-based narratives move faster than facts, the disciplined operator has an advantage. Documentation is not defensive. It is strategic.
Hemp does not need louder slogans. It needs better systems. The future of the industry will not be decided by how passionately it argues, but by how professionally it operates. Industries that master their processes earn the right to exist. Those that do not are regulated by people who assume chaos. Good Manufacturing Practice is not a burden. It is armor. And the companies that understand that first will shape what this market becomes next.
If you want to understand where the infused edible market is headed, do not look at flashy
billboards or exaggerated marketing copy. Look at the gummies.
The Blazed Magazine Gummy Challenge 2026 brought together some of the most ambitious
names in hemp-derived and cannabis-infused confections, from ultra-high potency heavy hitters
to carefully crafted, flavor-forward, low-dose experiences. Entries were evaluated across multiple
THC categories along with a dedicated mushroom category. Judges focused on flavor, texture,
consistency, ingredient integrity, onset time, and overall effect.
This year, the competition was exceptionally tight.
Mushroom Category Winner Muscimol Blue Crush by Spores MD
Taking the top spot in the mushroom category was Muscimol Blue Crush by Spores MD.
Unlike psilocybin products, muscimol is derived from Amanita muscaria and delivers a distinctly
different experience. Spores MD has positioned itself as a structured, formulation-focused brand
in a mushroom market that often lacks clarity. Their Blue Crush offering stood out for its clean
execution, consistent dosing, and balanced, calming effect profile.
In a category that can easily drift into novelty, Spores MD demonstrated discipline and product
maturity.
THC Categories
THC entries were divided into three potency tiers:
High THC 100mg+
Mid Range 50mg+
Standard Dose 10mg to 25mg –
Each tier was judged independently, acknowledging that a 200mg product serves a very different
consumer than a 10mg product.
High THC 100mg+ Winner
Looper, Mango Gelato
Looper’s Mango Gelato gummies entered the competition with striking potency numbers,
labeled at 100mg per gummy and 10,000mg per package.
It is important to clarify for readers that products in this high-dose hemp space often contain
blended cannabinoid formulations. The total milligram count may include a mixture of hemp-
derived THC isomers and other cannabinoids rather than 100mg of pure delta-9 THC alone. This
approach has become common in the federally compliant hemp market.
Looper has built a strong retail presence through smoke shops and online distribution, focusing
on bold flavors and intense effect profiles aimed at experienced consumers. Mango Gelato
delivered a pronounced tropical profile and a long-lasting, high-intensity experience that clearly
resonated in the 100mg+ division.
For high-tolerance consumers seeking maximum impact per serving, Looper secured the top
position.
50mg+ Winner Wyatt Purp, Lemon Bar
Wyatt Purp claimed first place in the 50mg+ category with its Lemon Bar entry.
The brand has developed a reputation for premium-style infused products that emphasize flavor
craftsmanship alongside cannabinoid formulation. The Lemon Bar gummy offered a bright citrus
profile with a clean finish and balanced sweetness.
On a personal note, the Wyatt Purp chocolates were my favorite products in the entire
competition. The chocolate was rich and smooth, with none of the artificial undertones that often
accompany infused confectionery. The effect was strong yet composed, delivering a euphoric and
comfortable experience rather than a jarring spike. It was a reminder that potency and pleasure
are not mutually exclusive.
Wyatt Purp demonstrated that elevated edibles can compete on culinary merit, not just milligram
count.
10mg to 25mg Winner T&T Roots, Peach and Guava
T&T Roots secured the top position in the standard-dose category with its Peach and Guava
gummies.
This potency range represents where most consumers operate day to day. T&T Roots focused on
flavor harmony and reliable dosing. The peach and guava pairing felt natural and layered rather
than artificially sweet. Lower-dose products leave no room to hide behind strength alone.
Execution matters. T&T Roots delivered.
Four Way Tie for Second Place
The THC competition was so competitive this year that four brands tied for second place:
The Haze Connect, Key Lime Pie
Fyre, Plum Vanilla Kush
3GCC, Blackberry
Freezo, Mimosa Mountain
The Haze Connect impressed with a dessert-forward citrus profile and a fast-acting formulation. Fyre balanced fruit and creamy vanilla undertones with a smooth cannabinoid blend.
3GCC, short for Gods 3rd Gen Craft Cannabis, leaned into a craft identity with a deep blackberry
profile and consistent texture. Freezo’s Mimosa Mountain, infused with live rosin, stood out for solventless appeal and terpene
presence rarely captured so clearly in gummy form.
Each of these brands brought a distinctive identity to the table, underscoring how far the edible
category has evolved.
Third Place
Endozondo, Citrus Peach
Endozondo earned third place with its Citrus Peach entry. Known primarily for its CBD roots,
Endozondo has expanded thoughtfully into broader cannabinoid formulations. Citrus Peach
offered bright flavor and a smooth onset that appealed to consumers seeking balanced, measured
effects rather than extreme potency.
What This Year’s Challenge Revealed
Several trends emerged from the 2026 competition.
Blended cannabinoid formulations continue to dominate the high-dose hemp market.
Flavor sophistication is rising, with dessert-inspired and fruit-layered profiles leading the way.
Live rosin and solventless infusions are carving out a premium niche within gummies.
Consumers remain divided between ultra-high potency seekers and those who prefer controlled,
moderate experiences.
Edibles are no longer a secondary category in cannabis and hemp. They are a primary innovation
lane. Brands are competing not only on strength but on refinement, consistency, and culinary
credibility.
The 2026 Blazed Magazine Gummy Challenge demonstrated that the bar has been raised.
And the category continues to mature.
Texas has a way of clarifying things. You can talk theory all day in a committee room, but sooner or later somebody’s boots hit the ground and you find out what the law actually means. That is where we are with federal cannabis policy right now—caught between a reform signal from the White House and the unmistakable sound of warehouse doors being kicked in.
In December 2025, President Donald Trump signed an executive order directing the federal government to move marijuana from Schedule I to Schedule III. That may sound like a bureaucratic reshuffling, but anyone who has spent time navigating the Controlled Substances Act knows the difference is not cosmetic. Schedule I is the legal fiction that cannabis has “no accepted medical use.” Schedule III acknowledges medical value and relaxes some of the most punitive structural burdens, including the tax regime that has strangled legitimate operators under Section 280E.
That was the signal from Washington: modernization. Alignment. A tacit admission that pretending cannabis belongs in the same federal category as heroin has become an exercise in self-parody.
And then came the raids.
The South Carolina Shock
In South Carolina, state and federal authorities executed sweeping enforcement actions targeting THC distributors under what prosecutors called “Operation Ganjapreneur.” Warehouses were searched. Trucks were seized. Thousands of pounds of product were confiscated. The rhetoric was familiar: highly intoxicating products, threats to children, narcotics charges.
Federal participation reportedly included the Drug Enforcement Administration, reminding everyone that even in a moment of federal policy transition, enforcement muscle remains fully flexed.
That is not an abstract policy debate. That is inventory in an evidence locker and people in handcuffs.
If you are an operator in Texas, that story does not feel distant. It feels like déjà vu.
Texas Has Lived This
We know this movie in Texas. We have watched hemp retailers operate in good faith under statutory language derived from the 2018 Farm Bill, only to find themselves facing seizures based on disputed lab interpretations. We have seen regulators struggle to reconcile evolving cannabinoid science with statutes drafted before anyone outside a chemistry lab had heard of delta-8. We have watched prosecutors test the outer edges of ambiguity because ambiguity is where discretion lives.
The 2018 Farm Bill did not hide its language. Hemp and all derivatives, extracts, cannabinoids, and isomers under 0.3 percent delta-9 THC were removed from the Controlled Substances Act. Congress wrote it. The President signed it. Markets responded. If legislators later decided the consequences were broader than anticipated, that is a drafting problem, not a smuggling conspiracy.
As James Madison warned in Federalist No. 62, “It will be of little avail to the people that the laws are made by men of their own choice if the laws be so voluminous that they cannot be read, or so incoherent that they cannot be understood.” We are living in the incoherence he feared.
The Republican Family Argument
This moment is not a clean partisan fight. It is an internal Republican argument.
Some lawmakers have publicly suggested that the President was “poorly advised” to move toward Schedule III. Their objection is procedural: that rescheduling amounts to an end-run around the FDA’s drug approval framework. Research, they argue, can proceed without altering federal classification.
That position is not merely technical. It reflects a worldview that treats drug scheduling as a cultural boundary marker. If you move the line, you concede ground.
On the other side are voices arguing that rescheduling is simply catching federal law up to political and medical reality. Longtime Trump ally Roger Stone has publicly urged the move, framing it as both substantively defensible and politically savvy. Cannabis reform polls well. Voters across party lines support medical access. The states have already moved.
This is not a debate about botany. It is a debate about governance and narrative.
The Culture-War Reflex
When enforcement rhetoric lumps cannabis together with fentanyl and cartel trafficking, the public hears a simple story: drugs are drugs. But cannabis is not fentanyl. Hemp-derived THC products sold in storefronts are not clandestine meth labs run by transnational syndicates.
Agencies like the Federal Bureau of Investigation understandably focus on dismantling violent criminal networks. That mission is legitimate and necessary. The danger arises when the language of that mission bleeds into areas where regulation, not eradication, is the appropriate tool.
Texas humor has a way of cutting through this. If you treat a mesquite bush like it’s a forest fire, you end up calling in helicopters for a backyard barbecue.
Reform Must Survive Contact with Reality
An executive order is direction. A raid is consequence.
If Schedule III becomes the operative federal posture, enforcement priorities should reflect that transition. That does not mean anarchy. It does not mean ignoring bad actors. It means calibrating response to actual harm rather than political optics.
The lesson from South Carolina is not that reform has failed. It is that reform without alignment creates instability. Businesses do not operate well in twilight zones. Investors do not deploy capital where statutory interpretation shifts by press conference.
Texas has every reason to watch this carefully. Our Legislature, our regulators, and our law enforcement agencies will inevitably confront the same tension between federal signals and state statutes. We can choose clarity through legislation and transparent rule-making, or we can choose episodic enforcement theatrics.
As Sam Houston once observed, “A leader is one who helps improve the lives of other people or improve the system they live under.” Modernizing cannabis policy is not about indulgence. It is about improving a system that has long been riddled with contradiction.
The story unfolding right now is not whether cannabis will remain controversial. It will. The story is whether American law can align itself with reality without swinging from neglect to overreaction.
Policy is not what is announced at a signing ceremony in Washington. Policy is what happens when the warrants are served and the courtroom doors close.
That is where reform proves itself—or exposes itself as rhetoric.
The next chapter of this series will examine what Schedule III actually changes on the ground and whether it meaningfully restrains the enforcement machinery we just watched in motion.
Because in Texas, we do not judge policy by applause lines.
Texas does not have a marijuana industry. It has a hemp industry that Congress legalized in 2018 when President Donald Trump signed the Agriculture Improvement Act of 2018 into law. That statute removed hemp and “all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers” containing no more than 0.3 percent delta-9 THC from the Controlled Substances Act. It was not ambiguous. It was not an accident. It was bipartisan and it was intentional.
Texas responded. Farmers planted. Processors invested. Retailers signed leases. An entire supply chain emerged around what is now a six-to-eight-billion-dollar Texas hemp market. That number is not a fever dream. It reflects retail, wholesale, manufacturing, logistics, and the secondary economic effects of a rapidly scaling consumer sector. Whether one likes the products or not, this is not a hobby economy.
And now we are in a trade war with China.
That matters.
Because if the stated national policy is economic sovereignty, domestic manufacturing, and protecting American supply chains from foreign capture, then the enforcement posture toward hemp deserves scrutiny. Texas entrepreneurs who relied on the text of the 2018 Farm Bill are facing regulatory whiplash and criminal exposure in some jurisdictions. At the same time, there is growing national concern about Chinese-linked criminal networks operating illegal marijuana grows in states with loose licensing systems, and about foreign chemical supply chains that feed gray and black markets in synthetic cannabinoids.
These are separate phenomena. But politically, they are colliding.
The hard question is this: are we protecting American producers, or are we destabilizing them while foreign competitors and illicit networks fill the vacuum?
If aggressive enforcement and regulatory ambiguity suppress domestic hemp operators in Texas, the market does not vanish. Consumer demand does not evaporate because a press conference was held. Markets adapt. Supply shifts. If legitimate, tax-paying Texas businesses are squeezed, the logical beneficiaries are out-of-state actors, offshore chemical suppliers, and illicit networks operating beyond transparent oversight.
That is not conjecture. It is how markets behave.
The intoxicating hemp segment exists because Congress legalized hemp broadly and because chemists learned how to work within that definition. THCa flower, delta-8, and other hemp-derived cannabinoids did not emerge from a conspiracy; they emerged from statutory text and innovation. Whether lawmakers now regret the breadth of that language is a separate political debate. But regret does not rewrite history.
If the United States is serious about economic competition with China, then domestic agricultural and manufacturing sectors should be strengthened, not destabilized through inconsistent interpretation. Texas hemp businesses are American small businesses. They hire locally. They pay Texas taxes. They lease Texas property. They operate under state registration systems.
One can argue for tighter standards. One can argue for clearer labeling. One can argue for age restrictions or potency caps. Those are regulatory debates. But criminalizing ambiguity while foreign supply chains remain fluid is not economic nationalism. It is self-inflicted asymmetry.
The China narrative is powerful because it taps into real anxieties about supply chain vulnerability, intellectual property theft, and chemical precursor markets. But it becomes incoherent if domestic entrepreneurs are treated as expendable collateral damage in the same breath.
Here is the uncomfortable tension: President Trump legalized hemp. Texas built an industry on that legalization. Now, in the middle of an escalating trade conflict with China, enforcement uncertainty threatens to push market share away from transparent American operators and toward actors far less accountable to U.S. regulators.
If we are in an economic war, strategy matters. You do not weaken your own productive base while invoking sovereignty.
Texas is uniquely exposed in this debate because of the size of its hemp economy and the state’s political alignment with national trade rhetoric. A six-to-eight-billion-dollar market is not a rounding error. It is jobs in Houston warehouses, manufacturing equipment in Dallas facilities, retail payroll in San Marcos strip centers, and rural acreage planted with hemp instead of fallow fields.
The question is not whether reform is needed. The question is whether reform strengthens domestic producers or drives capital offshore.
Nationalism, if it means anything, must include coherent domestic policy. Otherwise it becomes theater.
The Texas Department of State Health Services has formally extended the emergency rules governing consumable hemp products through March 30, 2026, as reflected in the February 6, 2026 Texas Register. These rules—first adopted in October 2025—remain in effect without substantive change. No new restrictions were added. No permanent rules were finalized.
This matters because the state had a choice. It could have locked in final rules and forced the issue legally and politically. Instead, it chose to extend temporary authority. That is not an accident. It is a pause.
The emergency extension keeps the current guardrails in place, including age-based sales restrictions, while avoiding a permanent regulatory position that would invite immediate legal challenge and legislative backlash. In plain terms, the state is holding its ground without planting a flag.
What this action does not do is just as important. It does not settle the future of hemp regulation in Texas. It does not expand enforcement authority. It does not criminalize new conduct. It does not resolve disputes over testing standards, product categories, or agency overreach. It simply preserves the status quo—briefly.
That brief preservation is the opportunity.
Emergency extensions are breathing room, not absolution. They create time for the industry to show whether it can operate credibly under scrutiny or whether the state will feel justified in tightening the vise. Every regulator and elected official understands this distinction, even if they do not say it out loud.
This is the moment when voluntary compliance stops being a philosophical preference and becomes a strategic necessity.
Certified training programs, documented age-gating, truth in labeling, truth in testing, verified brands, and clean supply chains are no longer just internal best practices. They are evidence. They are proof points that can be shown to the Governor’s Office and to legislators who are still persuadable. They answer the only question that really matters right now: Can this industry govern itself responsibly if allowed to continue operating?
Everything done during this window will be noticed. Good conduct compounds. Bad conduct will be amplified and used as justification for permanent restrictions that will be far harder to undo. There is no private behavior in this environment. There is only behavior that strengthens the case for rational regulation, or behavior that hands opponents exactly what they want.
Texas has not slammed the door. It has left it cracked open.
Whether that crack becomes a stable regulatory framework or snaps shut into overreach depends on what the industry does next. This window is real. It is short. And it should not be squandered.
The continued use of emergency rule renewals, rather than adoption of final rules, is not accidental and it is not merely procedural housekeeping. It reflects a deliberate choice by the agency to avoid locking itself into a permanent regulatory position while legal, political, and policy variables remain unsettled.
Final rules carry consequences that emergency rules do not. Once finalized, they invite immediate judicial review on a fuller record, expose the agency to greater litigation risk, and signal institutional confidence that the policy is both lawful and durable. By contrast, emergency renewals preserve flexibility. They allow the agency to maintain interim guardrails while avoiding a definitive commitment that could be overturned, enjoined, or politically repudiated.
The repeated reliance on emergency authority is therefore a tacit acknowledgment that the regulatory environment remains unstable. It suggests that DSHS understands its position is being watched closely by courts, the Legislature, and the Governor’s Office, and that moving too aggressively or too permanently could backfire. Emergency renewals buy time. They keep the status quo intact without forcing a showdown.
Politically, this matters. The absence of final rules signals that the industry has not lost the argument, even if it has not yet won it outright. The state is not declaring the matter settled. Instead, it is holding space—narrow space, but real space—while broader questions about statutory authority, public safety, economic impact, and administrative overreach continue to percolate.
That pause creates what amounts to breathing room, and breathing room only has value if it is used deliberately.
From a strategic standpoint, this is the window in which the industry must demonstrate maturity, seriousness, and good faith. Everything being done now—certified compliance education, standardized training for owners and employees, verified brand programs, age-gating protocols, and documentation of best practices—is not just about internal improvement. It is evidence. It is proof of concept. It is the answer to the unspoken question regulators and legislators are asking: Can this industry govern itself credibly if given the chance?
This is particularly relevant for engagement with Greg Abbott’s office and with legislators who remain persuadable rather than hostile. Emergency renewals create space for education. They allow time to show—not merely assert—that the industry has taken concrete steps to address safety, youth access, product integrity, and transparency. They also allow elected officials to absorb that information without having to immediately defend a yes-or-no vote.
At the same time, the moment comes with discipline requirements. The industry should assume that everything it does is being observed—by regulators, by lawmakers, by opponents, and by the press. There is no such thing as a private experiment right now. Good behavior compounds. Bad behavior will be amplified and weaponized. Compliance efforts that are real, documented, and independently verifiable strengthen the case for reasonable regulation. Sloppy conduct, internal infighting, or opportunism weaken it.
Legally, the signal is equally clear. Emergency renewals suggest that the agency is aware its footing is not yet secure. That awareness creates leverage, but only if the industry continues to build a record showing that education, certification, and verification are not theoretical aspirations but operating realities. Courts care about facts on the ground. Legislators care about political risk. The Governor’s Office cares about both.
In short, emergency rule renewals are the state pressing the pause button—not out of generosity, but out of caution. The industry has been given time, not absolution. Used wisely, this period can materially improve the odds of a durable, lawful, and rational regulatory framework. Used poorly, it will be cited later as proof that the opportunity was squandered.
The work now is not defensive panic. It is methodical proof-building. And in this environment, proof has a way of moving people who were previously content to sit on the fence.
For years, kratom existed in a regulatory gray zone—debated, periodically regulated, but rarely confronted through full-scale state enforcement. That equilibrium broke on February 6, 2026, when the Texas Attorney General filed suit in Ellis County seeking an ex parte temporary restraining order, temporary and permanent injunctions, and civil penalties against two smoke shop operators accused of selling illegal kratom products .
The State’s opening claim is blunt and unambiguous:
“Kratom is addictive and deadly.”
According to the petition, Texas health officials and lawmakers are no longer dealing with traditional botanical kratom, but with what the filing describes as “potent and dangerous concentrations of synthetic alkaloids” that bear little resemblance to the plant historically consumed in Southeast Asia .
The lawsuit alleges that products sold at Smokey’s Paradise retail locations contained 7-hydroxymitragynine (7-OH) at levels that “significantly exceed[] the 2% statutory limit” imposed by the Texas Kratom Consumer Health and Safety Protection Act. In some cases, laboratory testing allegedly found 7-OH making up “96% of the tablet”—a concentration the State characterizes as “forty-nine times the legal limit” .
Even more consequential is the State’s allegation that several products contained mitragynine pseudoindoxyl, a compound the petition states “is not a natural alkaloid present in botanical kratom leaves” and “must be synthetically produced” . Under Texas law, the presence of synthetic alkaloids alone is sufficient to render a kratom product illegal.
The petition identifies specific branded products allegedly purchased by investigators and sent for independent laboratory testing, including Dozo Perks 7-OH tablets, 7OHMZ 7-OH tablets, 7Tabz 7-OH tablets, 7O’Heaven 7-OH liquid shots, and Tahi Mahji tablets .
The State does not frame these allegations as technical violations. Instead, it situates them squarely within an opioid-risk narrative. The filing describes 7-OH as “a potent mu-opioid receptor agonist with pharmacological properties similar to morphine and fentanyl” and warns that products containing concentrated 7-OH can cause “respiratory depression, physical dependence, and withdrawal symptoms characteristic of classical opioids” .
From a legal standpoint, the enforcement posture is as aggressive as the rhetoric. The Attorney General argues that when a statute is violated, courts need not weigh competing harms. Citing Texas precedent, the petition states that “the status quo can never be the continuing violation of a law,” and that the State’s “inability to enforce its duly enacted laws clearly inflicts irreparable harm” .
That framing matters. It allows the State to seek immediate injunctive relief without the delays typically associated with protracted litigation. In practical terms, it means retailers can be ordered to stop selling an entire product category before any final ruling on the merits.
For legislators, the lawsuit provides something equally valuable: a ready-made factual record. The petition assembles poison-center data, FDA warnings, DEA classifications, and laboratory findings into a narrative that recasts kratom not as an herbal supplement with compliance problems, but as an emerging synthetic opioid threat. Once that framing is adopted, legislative outcomes tend to follow.
The implications extend beyond kratom alone. Regulators do not evaluate retail compliance in isolation. Stores alleged to sell illegal synthetic products are more likely to be viewed as systemic risks, a perception that can spill over into inspections, licensing decisions, and enforcement priorities affecting other product categories, including hemp-derived THC.
The Ellis County case is therefore best understood not as an isolated dispute, but as a template. It shows how kratom enforcement is likely to proceed and how legislative debates will be shaped going forward. The State has moved past warnings and into injunctions, past regulation and toward elimination.
For an industry accustomed to regulatory ambiguity, the message is suddenly precise. The kratom debate has entered its endgame, and the first decisive move has already been filed in court.
Texas lawmakers who once pushed for a total ban on hemp-derived THC products are now signaling a shift toward regulating the market instead of outlawing it — setting the stage for major hemp policy changes in the 2027 legislative session.
Earlier attempts by state leaders — especially a high-profile push to ban all consumable hemp THC products — failed to become law in recent legislative sessions. Instead of outright prohibition, elected officials are increasingly talking about building a regulatory framework that could offer clarity, safety standards and oversight for THC-containing hemp products.
At a recent cannabis policy conference, lawmakers on both sides of the aisle acknowledged that the status quo — where intoxicating hemp products occupy a legal gray area — isn’t working for businesses, public safety officials or consumers. Republican Rep. Drew Darby (R-San Angelo) said his view evolved after hearing testimony from veterans, small business owners and everyday Texans about the role hemp plays in their lives and livelihoods.
“I was predisposed toward prohibition,” Darby said, “but seeing the real-world impact — people finding relief, small businesses investing their futures — transformed how I think about this. Regulation, not prohibition, is the answer.”
The shift comes after years of debate in Austin over how to handle intoxicating hemp products like delta-8, delta-9 and THCA flower. Lawmakers previously advanced a bill that would have banned nearly all consumable THC products, but Governor Greg Abbott vetoed that measure, saying an outright ban was too extreme and could face legal challenges.
Lawmakers and industry stakeholders now expect the next step to be developing a comprehensive regulatory system — something akin to how alcohol and tobacco are overseen — instead of trying to ban hemp-derived THC outright. That could include standardized testing, age verification requirements and clear labeling rules designed to protect consumers while keeping the billions-dollar hemp market alive.
As Texas observers look ahead to 2027, many within the cannabis industry see this emerging regulatory approach as a practical compromise that could offer long-sought clarity for producers, retailers, and consumers alike — especially after years of contention over how hemp products should be treated under state law.
In a surprising move this week, Health and Human Services Secretary Robert F. Kennedy Jr. ordered the U.S. Department of Health and Human Services (HHS) to launch a federal review into the health effects of cellphone and wireless radiation, a topic long dismissed by government science. At the same time, the Food and Drug Administration (FDA) quietly removed longstanding webpages that said cellphone radiation posed no known health risk.
Kennedy’s decision has reignited debate over whether everyday wireless technology — from cell phones to Wi-Fi — may contribute to cancer or other health issues. Official federal agencies like the FDA, Centers for Disease Control and Prevention (CDC), and the National Cancer Institute have previously maintained there’s no solid evidence that radio-frequency (RF) radiation causes disease, and those existing statements are still up on some sites. But the removal of old FDA safety pages suggests a shift in tone and could clear the way for new research and possible policy changes.
Critics say this might just reopen old arguments without leading to real regulation, while supporters argue it’s a long-overdue reassessment of decades of research and lobbying influence. The new federal review — backed in part by the administration’s “Make America Healthy Again” initiative — aims to examine gaps in the science and push beyond outdated conclusions.
Whether this marks a genuine turning point in how wireless technology is regulated — or simply stirs up more controversy — remains to be seen, but one thing’s certain: the cellphone radiation debate is back on the front burner.
The Texas Supreme Court’s hearing in Texas Department of State Health Services v. Sky Marketing had the calm, deliberate feel of a court doing what courts are supposed to do: strip away the noise, ignore the moral-panic political theatrics across the plaza in the east wing of the Capitol, and read the statute because that’s what matters. The case arrives dressed in administrative-law vocabulary—standing, sovereign immunity, ultra vires, temporary injunction mechanics—but everyone in the room understood the real stakes. Texas legalized hemp in 2019, a regulated market formed in reliance on that law, and then an agency announced a reinterpretation that snapped the market’s spine. The question now is whether that kind of regulatory whiplash can be insulated from judicial review by calling it a “clarification.”
I’ve watched this dispute evolve since the beginning, from district court record-building to today’s argument. That history matters because what looks like a narrow legal fight from a distance is, up close, a case about institutional limits and whether agencies may do by administrative maneuver what the Legislature would not—or could not—do by statute. And this case potentially sets the stage for a challenge to the latest iteration of government by gaslight—the DSHS proposed permanent hemp rules (see previous article.)
The justices’ questions signaled an important choice point. They were not there to referee policy preferences about delta-8, hemp-derived intoxicants, or the cultural anxieties legislators like to launder through “for the children” messaging. They were there to test the boundaries of delegated authority, the coherence of the State’s standing theory, and the legitimacy of using regulatory communication as a substitute for formal rulemaking.
The State’s Framing: “Longstanding Efforts” and a “Clarification”
Arguing for the State, Ryan Scanlon, in his capacity as Assistant Solicitor General, opened with a familiar frame: Texas has long tried to control THC, “the high-inducing substance naturally found in the cannabis plant,” and Texas’s hemp program was never meant to be “a legally permissible vehicle for the proliferation of synthetic and intoxicating forms of that drug.”
That opening is not accidental. It tries to position the case as a continuity story—Texas doing what Texas has always done—so that the agency’s 2021 action reads as inevitable maintenance rather than a material shift. Scanlon pushed that theme hard. On the merits, he argued the Commissioner did not “place delta-8 on the schedule,” because delta-8 is simply “a form of THC,” and “THC has always been on the schedule.” What happened, he insisted, was “a clarification.”
The legal strategy underneath that word choice is obvious. If it was only a clarification, then the case starts to look like an attempt to litigate policy through injunctive relief, rather than a challenge to an agency action that exceeded statutory authority. If it was only a clarification, the State wants the Court to treat the economic disruption as either irrelevant or not fairly traceable to the Commissioner’s action. If it was only a clarification, the injunction looks like an improper universal freeze of “the effectiveness of the amendments,” instead of a conventional restraint on unlawful enforcement.
The justices did not accept that premise as a given. They treated “clarification” as a claim that must survive contact with consequences.
Standing: The State’s Escape Hatch Meets the Real World
Scanlon leaned heavily on standing and sovereign immunity. His core point was that the Commissioner sets the schedules but does not enforce the criminal law. Without criminal enforcement authority, the State argued, challengers cannot establish standing to sue this official, and sovereign immunity bars the suit.
The Court immediately started probing the reality behind that doctrinal posture. One justice asked the basic question any regulated business would ask: if a party may be prosecuted for violating the rule, does it matter who initiates it? Scanlon answered that it does matter, invoking this Court’s 2020 reasoning in Abbott—if the official you sued cannot bring a criminal prosecution, you may lack standing.
That line of argument has a certain internal elegance, but it runs into the way regulation actually works in Texas. Modern regulatory harm does not wait politely for an indictment. It arrives through licensing consequences, market signals, official statements, and the chilling effect of uncertainty.
Justice Rebeca Huddle went straight to that point. “What about the civil side?” she asked. “Don’t they have authority to revoke a license, issue monetary penalties? What about them?”
Scanlon conceded there is civil authority, but then tried to escape it: those allegations, he said, were not pleaded, and in any event the civil licensing scheme “has nothing to do with the Controlled Substances Act.”
That answer prompted something close to the central standing issue in this case: if the Commissioner’s scheduling decision changes what products are treated as lawful, how can the State insist there is no traceable injury to regulated businesses? Justice Crosby pressed that logic, noting the respondents’ evidence that they lost money because they could no longer market certain products. Scanlon’s response was essentially that licensing only applies once the product is already a legal hemp product—and therefore scheduling cannot be the cause of their injury.
The bench treated that as a merits question wearing a standing costume. If the whole fight is whether the Commissioner’s action reclassified what counts as a legal hemp product, then saying “licensing only applies to legal hemp products” just restates the dispute. You can’t resolve standing by assuming your own conclusion.
A separate justice sharpened it further: the Court recognizes “standing for a pocketbook injury,” and if businesses are “losing money because of something your client did,” why isn’t that enough? Scanlon tried to cabin pocketbook standing to rate cases and reimbursement settings where the agency action directly sets a number. He argued this case lacks that directness.
That answer did not appear to satisfy the bench’s concern, because the Court kept returning to consequence: the economic disruption was not hypothetical; it was immediate; and it tracked the agency’s public posture. When Scanlon was asked whether the Commissioner had “threatened enforcement,” he responded bluntly: “The Commissioner has not threatened enforcement.”
That is where the State’s standing theory begins to look like an attempt to convert regulatory power into accountability-free power. If an agency can announce a new interpretation that chills the market, triggers compliance retreat, and collapses investment, and then claim there is no standing because it did not personally make an arrest, the Court is left endorsing a model of governance where the most economically destructive tools are the least reviewable.
The justices’ questions suggested they understand that trap.
The Court Tests the “Clarification” Story
The most important pressure the Court applied today was conceptual. The justices kept returning to the mismatch between the State’s description of its action and the industry’s lived reality.
Justice Bland asked one of the most consequential questions: what is the State’s best argument that treating delta-8 as controlled does not conflict with the definition of hemp in the Texas farm bill?
Scanlon’s response was to double down: delta-8 wasn’t “placed” on the schedule; it is THC; THC was always scheduled; the Commissioner merely clarified after federal changes.
Then came the chemistry and process discussion. Bland asked whether delta-8 is derived or extracted from the cannabis plant. Scanlon answered with a layered explanation: not directly from hemp, he suggested, but from CBD extracted from hemp, with a synthesis process described by CDC and FDA. In other words, delta-8 in commercial form is typically manufactured through chemical conversion rather than extracted as-is at scale.
Scanlon leaned on the DEA observation that in a natural hemp plant under the delta-9 threshold, delta-8 appears only in trace amounts; therefore, when Texas law talks about THCs in hemp, it is talking about naturally occurring trace presence, not manufactured potency.
That framing is politically useful—“trace amounts good, manufactured intoxicants bad”—but it has a legal problem: the Legislature wrote a definition that includes derivatives and isomers and drew the line at delta-9 concentration. If the Legislature intended to prohibit conversion manufacturing or to outlaw certain isomers regardless of delta-9, it had ample opportunity to say so. The State is now asking the Court to infer a narrower legislative intent from federal agency commentary and chemical process descriptions.
That is precisely the sort of move Texas courts scrutinize when assessing ultra vires conduct.
Taylor’s Presentation: Calm, Clear, and Commanding
When Amanda Taylor rose for Sky Marketing, the tonal shift in the courtroom was immediate. Some advocates respond to questions as if they’re being interrupted. Taylor responded as if the justices were doing her a favor by letting her show her work. She framed the case where it belongs: “the bounds of the agency authority expressly delegated by our Legislature.” Policy debates about hemp might be “interesting or controversial,” she said, but the Court’s job is to say what the law means and apply it.
That opening did two things at once. It reduced the State’s moralizing posture to background noise, and it invited the justices to act like judges rather than referees in a culture fight.
Justice Bland asked the key threshold question: is the Commissioner’s decision subject to judicial review? Taylor answered without flinching: yes. Then she did what excellent appellate lawyers do: she took the State’s statutory hook—subsection G—and narrowed it to its actual scope. Subsection G, she explained, addresses the decision whether to conform with federal scheduling changes; it does not authorize the Commissioner to “unilaterally modify the schedule and make it inconsistent with existing Texas law.”
Taylor’s most effective moment came when she confronted the “clarification” label. If the State truly believes no legally significant change occurred, why is the action ultra vires? Taylor’s answer was crisp and procedural: subsection G permits only one type of change—conform or decline. Any “alteration other than the federal conformance change” must proceed under subsection B, which requires notice and hearing on the modification itself, not merely on an objection.
Then she layered in the additional statutory failures: missing findings, failure to notify other agencies with overlapping authority within ten days, and lack of required approval by the Executive Commissioner of HHSC. “None of that occurred.”
Her delivery was exactly what you want when you’re asking a court to enforce limits on agency power: clear, smooth, unruffled, and relentlessly grounded in the statutory roadmap. She sounded like someone who had read the whole record, not just the parts that make her point.
The Legislature’s Hemp Line: Delta-9 as the Bright Line
Taylor also anchored the case in the 2019 hemp framework in a way that forced the Court to confront the Legislature’s design. The statute, she argued, says hemp and THC in hemp are not controlled substances, with legality limited by delta-9: above 0.3% delta-9 is marijuana; below is hemp and not controlled.
That matters because the State’s position tries to smuggle in a different legality test: not the delta-9 threshold, but a broader concept of “THC isomers and analogs” depending on origin or manufacturing method. Once you move away from the statute’s bright line and toward agency-driven categorization, you effectively rewrite the Legislature’s compromise.
Justice Young pressed on delegation—this is an area where the Legislature delegates heavily, so why do we need the statutory limits Taylor was invoking? Taylor’s response was grounded in the 2019 statute’s explicitness: the definition includes derivatives and isomers, and it defines processing and manufacturing in a way that contemplates a regulated consumable market, including conversion and manufacturing.
She also addressed the State’s “synthetics” obsession with a controlled burn. “This lawsuit is not about synthetics,” she said. The State used that word “throughout the State’s brief,” but Sky Marketing did not seek relief tied to that language. This case was brought by businesses and consumers producing and using “legal consumable products made from naturally derived substances.”
That was not mere positioning. It was a strategic narrowing designed to keep the Court from being pulled into a broader political fight the State would prefer to litigate in moral terms.
The Injunction and the Court’s Discomfort with a Universal Freeze
Another line of questioning the Court pressed with particular care concerned the form of the temporary injunction itself. One justice focused on whether the order had slipped from party-specific relief into something broader, noting that it appeared to restrain the “effectiveness of the amendments,” rather than simply prohibiting their enforcement against the plaintiffs. Framed that way, the concern was not semantic but structural: whether the injunction operated in rem rather than in personam.
Taylor met the question head-on. The injunction, she explained, was prospective relief designed to prevent ongoing harm while the merits are litigated, not a judicial repeal of the statute or rules. The language may have been broad, but its function was conventional: to restrain unlawful enforcement of an ultra vires action pending judicial review. She pointed the Court to precedent recognizing that courts routinely prevent continued harm from invalid agency action without purporting to legislate for nonparties.
The State countered that the injunction crossed a constitutional line. By enjoining the “effectiveness” of the scheduling amendments, it argued, the trial court had issued relief that functioned universally, not merely against the named defendants. That, in the State’s telling, transformed a routine injunction into a policy freeze—precisely the sort of relief Texas courts have grown wary of in recent years.
What made the exchange consequential was not the labels, but the Court’s evident concern with how injunctions operate in practice. Texas courts have repeatedly cautioned against orders that look less like dispute resolution and more like administrative suspension. The justices’ questions reflected that unease.
In rebuttal, Scanlon appeared less prepared on this ground. He acknowledged that he had not fully briefed the universal-injunction issue and asked for the opportunity to address it later. That moment lingered, because it reinforced a pattern already visible in the argument: a reliance on formal categorization where the Court was probing functional effect.
The critique of the State’s presentation crystallized there. Scanlon’s advocacy was confident and technically fluent, but it repeatedly assumed that doctrinal labels—“clarification,” “no enforcement authority,” “separate licensing scheme”—were sufficient answers, even when they failed to account for what actually happened to the regulated community. As the bench pressed on scope and consequence, the answers drifted toward procedural abstraction.
Taylor, by contrast, made the Court’s work easier. She offered clean handles rather than evasions: a statute with a clear roadmap, identifiable procedural failures, and a theory of harm that aligned with how regulation actually operates in the real world. That difference in approach mattered, because the Court was plainly less interested in how the injunction was described than in whether it functioned as a proper exercise of equity.The Hearing’s Quiet Theme: Consequences Count
Perhaps the most telling aspect of the argument was how frequently the justices returned to consequences—economic injury, compliance whiplash, and the real-world effects of regulatory signaling. The State tried to confine the case to the absence of criminal enforcement and the formal separateness of licensing from scheduling. The bench kept tugging back toward what happens when an agency speaks and the market believes it must obey.
Taylor captured the point in her standing discussion, emphasizing that the agency’s website statement operates as a threat and that the State has not disclaimed intent to enforce. The record, she noted, showed “immediate economic disruption” once the policy was announced: businesses stopped selling products; reputations were harmed; layoffs were considered.
When the Chief Justice closed the argument, the case was submitted with the sense that the Court had identified the case’s true center of gravity: not whether delta-8 is controversial, but whether the law permits an agency to accomplish a substantive change under the banner of refusing a federal change, without following the statutory procedure for changing Texas law.
Why This Case Matters to the Structure of Texas Government
Texas has lived for years inside a mismatch: the Legislature wrote a definition and a bright line in 2019, the market organized itself around that line, and then agencies and political actors tried to claw back ground through reinterpretation and enforcement posture. That conflict will not end until either the Legislature redraws the statute clearly or the courts enforce the boundaries of delegation.
If the State’s theory prevails, agencies gain a path to reshape statutory meaning through public posture and interpretive maneuvers, insulated by standing doctrine so long as they avoid being the official who files charges. That model expands administrative power while shrinking accountability.
If Sky Marketing’s theory prevails, the Court reaffirms something Texas needs right now: delegated authority has limits, and those limits still bind even when politics gets impatient.
Amanda Taylor argued that position with clarity, smoothness, and a calm command of the record and the law that never wavered. Ryan Scanlon, serving as Assistant Solicitor General, offered a theory that was formally neat but repeatedly struggled to match consequence with characterization. The justices noticed. They pressed. They circled back. They kept asking the same question from different angles until the contradiction could no longer hide behind labels.
Let’s hope that kind of judicial rigor still counts where it matters.
Author
The author was an initial plaintiff and later a witness in this case at the district court level and assisted in recruiting some of the plaintiffs and counsel. At the time, he served as Executive Director of the Texas Hemp Federation and worked closely with the former leadership of Hometown Hero, whose parent company, Sky Marketing, is the named respondent here.
That perspective is offered not to personalize the outcome, but to explain why the Court’s questions resonated so strongly. The author has seen, under oath and in real time, how regulatory ambiguity is created and how quickly it can destabilize manufacturers, distributors and wholesalers, and retailers operating in good faith. The issues before the Supreme Court today are the same ones the trial court confronted years ago, and they remain the right ones.
Regulation Over Prohibition
A Billion-Dollar Battle
The Bigger Picture
Bottom Line
